Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials

References

• Ford JH, Foster SA, Nichols RM, et al. A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe. J Patient Rep Outcomes. 2020;4(1):630.
   Google Scholar
• Vo P, Paris N, Bilitou A, et al. Burden of migraine in Europe using self-reported digital diary data from the migraine buddy(c) application. Neurol Ther. 2018;7(2):321–332.
   PubMed Web of Science ®Google Scholar
• Yucel A, Thach A, Kumar S, et al. Estimating the economic burden of migraine on US employers. Am J Managed Care. 2020;26(12):e403–e408.
   PubMed Web of Science ®Google Scholar
• Agosti R. Migraine burden of disease: from the patient's experience to a socio-economic view. Headache. 2018;58(Suppl 1):17–32.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Sakai F, Miyake H, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22(1):29.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Sapra S, Shah N, et al. Direct, indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. Avaibale on https://www.ajmc.com/view/study-summary-costs-associated-with-migraine-in-the-united-states.
   Google Scholar
• Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the eurolight project. Eur J Neurol. 2012;19(5):703–711.
   PubMed Web of Science ®Google Scholar
• Haw NJ, Cabaluna IT, Kaw GE, et al. A cross-sectional study on the burden and impact of migraine on work productivity and quality of life in selected workplaces in the Philippines. J Headache Pain. 2020;21(1):125.
   PubMed Web of Science ®Google Scholar
• Negro A, Sciattella P, Rossi D, et al. Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. J Headache Pain. 2019;20(1):120.
   PubMed Web of Science ®Google Scholar
• Polson M, Williams TD, Speicher LC, et al. [cited 2021 October 4]. Available from: https://www.ajmc.com/view/total-cost-of-care-in-patients-with-migraine-a-realworld-claims-analysis.
   Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454.
   PubMed Web of Science ®Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e2221.
   PubMed Web of Science ®Google Scholar
• Mulleners WM, Kim BK, Lainez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814–825.
   PubMed Web of Science ®Google Scholar
• Ford J, Tassorelli C, Leroux E, et al. Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN). Qual Life Res. 2021;30(1):105–115.
   PubMed Web of Science ®Google Scholar
• Smitherman TA, Tietjen GE, Schuh K, et al. Efficacy of galcanezumab for migraine prevention in patients with a medical history of anxiety and/or depression: a post hoc analysis of the phase 3, randomized, double-blind, placebo-controlled REGAIN, and pooled EVOLVE-1 and EVOLVE-2 studies. Headache. 2020;60(10):2202–2219.
   PubMed Web of Science ®Google Scholar
• Porter JK, Di Tanna GL, Lipton RB, et al. Costs of acute headache medication use and productivity losses among patients with migraine: insights from three randomized controlled trials. Pharmacoecon Open. 2019;3(3):411–417.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337–1345.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (HIS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.
   PubMed Web of Science ®Google Scholar
• Gross Domestic Product (GDP), per capita, international $(PPP-adjusted). [cited 2021 October 4]. Available on https://www.who.int/data/gho/indicator-metadata-registry/imr-details/1145.
   Google Scholar
• Work Productivity and Activity Impairment Questionnaire: General Health V2.0 (WPAI:GH). [cited 2021 August 2]. Available on http://oml.eular.org/sysModules/obxOML/docs/id_98/WPAI-GH_English_US_V2.pdf.
   Google Scholar
• The Migraine Disability Assessment Test. [cited 2021 June 15]. Available on https://headaches.org/wp-content/uploads/2018/02/MIDAS.pdf.
   Google Scholar
• Ford JH, Tockhorn-Heidenreich A, Nichols RM, et al. Annual Indirect Cost Savings in Patients with Episodic or Chronic Migraine: Post-hoc Analyses from Multiple Galcanezumab Clinical Trials (P-78). 63rd Annual Scientific Meeting American Headache Society. [cited 2021 October 21]. Available from: 10.1111/head.14130.
   Google Scholar
• World Economic Outlook Database. Gross Domestic Product Per Capita 2021. US. [cited 2021 August 2]. Available on https://www.imf.org/en/Publications/WEO/weo-database/2021/April/select-country-group.
   Google Scholar
• Work Productivity and Activity Impairment Questionnaire: General Health V2.0 (WPAI:GH). [cited 2021 October 4]. Available on https://oml.eular.org/sysModules/obxOML/docs/id_98/WPAI-GH_English_US_V2.pdf.
   Google Scholar
• Lubloy A. Economic burden of migraine in Latvia and Lithuania: direct and indirect costs. BMC Public Health. 2019;19(1):1242.
   PubMed Web of Science ®Google Scholar
• Seddik AH, Schiener C, Ostwald DA, et al. Social impact of prophylactic migraine treatments in Germany: a state-transition and open cohort approach. Value Health. 2021;24(10):1446–1453.
   PubMed Web of Science ®Google Scholar
• Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people's life. J Headache Pain. 2019;20(1):41.
   PubMed Web of Science ®Google Scholar
• Buse DC, Yugrakh MS, Lee LK, et al. Burden of illness among people with migraine and >/= 4 monthly headache days while using acute and/or preventive prescription medications for migraine. JMCP. 2020;26(10):1334–1343.
   PubMed Web of Science ®Google Scholar
• Burton WN, Chen CY, Li X, et al. Evaluation of a workplace-based migraine education program. J Occup Environ Med. 2016;58(8):790–795.
   PubMed Web of Science ®Google Scholar
• Yu J, Smith KJ, Brixner DI. Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application. CNS Drugs. 2010;24(8):695–712.
   PubMed Web of Science ®Google Scholar
• Thomas H, Kothari SF, Husoy A, et al. The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries. J Headache Pain. 2021;22(1):153.
   PubMed Web of Science ®Google Scholar
• Pradeep R, Nemichandra SC, Harsha S, et al. Migraine disability, quality of life, and its predictors. Ann Neurosci. 2020;27(1):18–23.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Wood GC, Bruce C, et al. Longitudinal change in migraine headache-days and indirect cost consequences. J Occup Environ Med. 2011;53(5):478–487.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22–33.
   PubMed Web of Science ®Google Scholar
• Seng EK, Singer AB, Metts C, et al. Does mindfulness-based cognitive therapy for migraine reduce migraine-related disability in people with episodic and chronic migraine? A phase 2b pilot randomized clinical trial. Headache. 2019;59(9):1448–1467.
   PubMed Web of Science ®Google Scholar
• Tinelli M, Leonardi M, Paemeleire K, et al. Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology. J Headache Pain. 2021;22(1):99.
   PubMed Web of Science ®Google Scholar
• Tinelli M, Leonardi M, Paemeleire K, et al. Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions. J Headache Pain. 2021;22(1):90.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Kolodner KB, et al. Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88(1):41–52.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Schwedt TJ, Vo P, et al. Healthcare resource use and indirect costs associated with migraine in Italy: results from the my migraine voice survey. J Med Econ. 2021;24(1):717–726.
   PubMed Web of Science ®Google Scholar
• Varnado O, Manjelievskaia J, Ford F, et al. P0218. Adherence and persistence to preventive migraine treatments over 12 months follow-up for patients with migraine: calcitonin gene-related peptide monoclonal antibodies versus other preventive treatments. Cephalalgia. 2021;41(1S):1–227.
   PubMedGoogle Scholar
• Reilly MC, Bracco A, Ricci JF, et al. The validity and accuracy of the work productivity and activity impairment questionnaire–irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther. 2004;20(4):459–467.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Dowson AJ, et al. Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20–S8.
   PubMed Web of Science ®Google Scholar